Clinical Guidelines & Position Statements

Publication Date

UPDATED: CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs.

  • Click here to view the latest version of the guideline on MAGICapp
  • Published versions of the guideline in Journal of Rheumatology:
  • Click here to view patient decision aid: Your Rheumatoid Arthritis (RA) is Well Controlled with a Biologic or Targeted Medicine: Should you Take Less Medicine?
August 2023
NEW: Position Statements on Priority Areas to Support the Sustainability of the Canadian Rheumatology Workforce December 2022
UPDATED: CRA Position Statement on Canadian Access to Citrate-free Adalimumab  November 2022
UPDATED: CRA Position Statement on Biosimilars November 2022
The CRA living guidelines for the Screening, Monitoring and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

  • Click here to view on MAGICapp
  • Click here to view published manuscript in the Journal of Rheumatology
October 2022
Bridging the Gaps: Optimizing the Transition from Pediatric to Adult Rheumatology Care July 2022
Updated CRA Position Statement on COVID-19 Vaccination (PDF) March 2022
CRA Recommendation on Three Doses of mRNA Vaccine for Preventing COVID-19 November 2021
Updated CRA Recommendation on COVID-19 Vaccination in Persons with Autoimmune Rheumatic Disease (PDF)
Submit public comment here
Decision Tool available here
November 2021
CRA Consensus Statement on the Best Practices for Virtual Care in Rheumatology
Includes PowerPoint slide infographic
September 2021
CRA Position Statement on Virtual Care (PDF) April 2021
CRA Position Statement on Safety of Hydroxychloroquine in the Treatment of Rheumatic Diseases (PDF) January 2021
CRA Position Statement on COVID-19 and Hydroxychloroquine Supply (PDF)
Frequently Asked Questions
April 2020
Canadian Rheumatology Association Policy on Potential Conflicts of Interest in the Guideline Development Process (PDF) June 2019
Canadian Rheumatology Association Guidelines Handbook (PDF) May 2019
Canadian Rheumatology Association Position Statement on Medical Cannabis Use in Rheumatic Disease
Frequently Asked Questions
January 2019
Canadian Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus August 2018
Canadian Position Statement on Opioid Therapy (PDF) November 2017
Canadian Position Statement on Management of Juvenile Idiopathic Arthritis October 2016
Canadian Position Statement on Ethical Prescribing (PDF) November 2015
Editorial: Expanding Medical Marijuana Access in Canada (PDF) November 2015
Canadian Review on Cannabinoid Treatments for Rheumatic Diseases  November 2015
Canadian Recommendations for the Management of Spondyloarthropathy April 2014
Cardiovascular Risk with Diclofenac:  Response to Health Canada (PDF)
Reviewed by Therapeutics Committee in November 2021 and no changes made.
November 2014
Chronic pain, Diclofenac and Cardiovascular Risk:  Management Algorithm (PDF) June 2014
Canadian Confidence with Cannabinoids in Rheumatic Diseases:  A Survey of Rheumatologists (PDF) November 2014
Canadian Recommendations for Management of RA August 2012
Canadian Fibromyalgia Guidelines August 2012